Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Stroke. 2016 Dec 27;48(2):459–467. doi: 10.1161/STROKEAHA.116.015592

Figure 4.

Figure 4

ABCA1−B/−B decreased ABCA1/Syn level and neurite/axonal outgrowth in PCNs. GW3965-treatment increased ABCA1/Syn levels and neurite/axonal outgrowth in ABCA1fl/fl-PCNs, but not in ABCA1−B/−B–PCNs after OGD; HDL attenuated ABCA1−B/−B–induced neurite/axonal outgrowth with or without hypoxic condition. A: WB image and quantitative data of WB and RT-PCR; B: Neurite-outgrowth after OGD and quantitative data; C: Axonal-outgrowth and quantitative data. *p<0.05, n=6/group.